EGFR-IN-182

EGFR-IN-182 (Compound 4) is an EGFR inhibitor with an IC50 value of 199 nM. It additionally inhibits HSP90 and PI3K, with IC50 values of 5.007 μM and 13.596 μM, respectively. EGFR-IN-182 demonstrates potent antiproliferative activity against MCF-7 and MDA-MB-231 cells. It downregulates Cyclin D1, induces cell cycle arrest, enhances caspase-9 activity, and triggers apoptosis. EGFR-IN-182 also decreases the expression of ERK and AKT and is applicable for breast cancer research.